Impact of Taiwan's Generic Drug Pricing Policy on Cardiovascular Drug Costs
Author Information
Author(s): Chen Chi-Liang, Chen Likwang, Yang Wei-Chih
Primary Institution: National Health Research Institutes
Hypothesis
The study hypothesizes that the reimbursement rate adjustment for pharmaceuticals will reduce daily drug expenses for patients in the exposure group.
Conclusion
The price adjustment action significantly reduced daily expenses for cardiovascular drugs, but led to increased total expenditures due to expanded prescription volumes.
Supporting Evidence
- The daily drug expense significantly decreased for the exposure group after the price adjustment.
- Total expenditures for cardiovascular drugs increased for both exposure and comparison groups post-action.
- Approximately 50% of patients received more than 180 days of prescription drugs in the post-action period.
Takeaway
The government tried to lower drug prices, but hospitals ended up giving out more medicine, which made total costs go up.
Methodology
The study used longitudinal data from 200,000 NHI enrollees to compare drug expenses and consumption before and after the 2001 price adjustment.
Potential Biases
Potential manipulation of prescription volumes by hospitals to increase reimbursements.
Limitations
The study could not directly examine hospitals' purchasing prices for pharmaceuticals, limiting insights into profit influences on drug choices.
Participant Demographics
Patients with chronic conditions, primarily hypertension, managed in hospitals under Taiwan's National Health Insurance.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI of change measured in %
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website